Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 17/20 | 0.62 |
| ▸ | CA1 | P00915 | 16/20 | 0.62 |
| ▸ | CA2 | P00918 | 16/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 7/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401673 | 0.90 | CA9 (0.61) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL14297780 | 0.90 | CA9 (0.59) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL15372440 | 0.89 | CA9 (0.59) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL15145504 | 0.89 | CA9 (0.63) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL14426895 | 0.87 | USP2 (0.68) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL14526777 | 0.86 | CA9 (0.56) | CA9CA1CA2USP2L3MBTL1 | |
| 5-Iodoacetamidofluorescein SCHEMBL10146553 | 0.86 | CA9 (0.66) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL14527509 | 0.86 | CA9 (0.66) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL12793932 | 0.86 | CA9 (0.66) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL412012 | 0.85 | CA9 (0.78) | CA9CA1CA2USP2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3079657-B1 | PREPARATION FOR PREVENTION AND/OR TREATMENT OF PERI-IMPLANTITIS | RLS GLOBAL AB (SE) | 2019-03-20 | — | — | EP | disclosed |
| US-9642780-B2 | Detection and removal of carious dentin tissue | RLS GLOBAL AB (SE) | 2017-05-09 | — | — | US | disclosed |
| US-9642780-B2 | Detection and removal of carious dentin tissue | RLS GLOBAL AB (SE) | 2017-05-09 | — | — | US | disclosed |
| US-20160310525-A1 | PREPARATION FOR PREVENTION AND/OR TREATMENT OF PERI-IMPLANTITIS | RLS GLOBAL AB (SE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310525-A1 | PREPARATION FOR PREVENTION AND/OR TREATMENT OF PERI-IMPLANTITIS | RLS GLOBAL AB (SE) | 2016-10-27 | — | — | US | disclosed |
| US-20150313801-A1 | DETECTION OF CARIOUS DENTIN TISSUE AND REMOVAL THEREOF BY MEANS OF A DENTAL INSTRUMENT | RLS GLOBAL AB (SE) | 2015-11-05 | — | — | US | disclosed |
| US-20150313801-A1 | DETECTION OF CARIOUS DENTIN TISSUE AND REMOVAL THEREOF BY MEANS OF A DENTAL INSTRUMENT | RLS GLOBAL AB (SE) | 2015-11-05 | — | — | US | disclosed |
| EP-2925275-A2 | DETECTION OF CARIOUS DENTIN TISSUE AND REMOVAL THEREOF BY MEANS OF A DENTAL INSTRUMENT | RLS GLOBAL AB (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2015086535-A1 | PREPARATION FOR PREVENTION AND/OR TREATMENT OF PERI-IMPLANTITIS | RLS GLOBAL AB (SE) | 2015-06-18 | — | — | WO | disclosed |
| US-20140161745-A1 | DETECTION AND REMOVAL OF CARIOUS DENTIN TISSUE | RLS GLOBAL AB (SE) | 2014-06-12 | — | — | US | disclosed |
| US-20070172915-A1 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070172915-A1 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-26 | — | — | US | disclosed |
| US-7238510-B2 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238510-B2 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-03 | — | — | US | disclosed |
| US-7217809-B2 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217809-B2 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-15 | — | — | US | disclosed |
| US-7199222-B2 | An artificial mutant tRNA synthetase; aminoacylates an orthogonal tRNA with beta -GlcNAc-serine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199222-B2 | An artificial mutant tRNA synthetase; aminoacylates an orthogonal tRNA with beta -GlcNAc-serine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-04-03 | — | — | US | disclosed |
| US-7183082-B2 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183082-B2 | Glycoprotein synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310525-A1 | PREPARATION FOR PREVENTION AND/OR TREATMENT OF PERI-IMPLANTITIS | KIT, CXCL8, GCG | CA9 1333/4885CA1 1065/4885CA2 2084/4885 |
| US-20140161745-A1 | DETECTION AND REMOVAL OF CARIOUS DENTIN TISSUE | CTRL, KLK5, KLK1 | CA9 36/4885CA1 6/4885CA2 18/4885 |
| US-20150313801-A1 | DETECTION OF CARIOUS DENTIN TISSUE AND REMOVAL THEREOF BY MEANS OF A DENTAL INSTRUMENT | NUCB2, HRH2, DACH1 | CA9 420/4885CA1 475/4885CA2 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.